07:00 , Oct 15, 2012 |  BioCentury  |  Strategy

At home with Servier

Rather than follow in the footsteps of other foundation-backed mid-size European pharmas that have largely concentrated on a single therapeutic area and looked to new markets for growth, Servier has determined its path to sustainability...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Company News

Cortex Pharmaceuticals, Servier deal

Servier exercised an option from Cortex to license exclusive, worldwide rights to develop and commercialize CX1632 . Cortex will receive $2 million up front, and is eligible for milestones and royalties. Servier paid Cortex $1...
00:46 , Oct 7, 2011 |  BC Extra  |  Company News

Servier exercises option for Cortex's CX1632

Servier (Neuilly-sur-Seine, France) exercised an option from Cortex Pharmaceuticals Inc. (OTCBB:CORX) to license exclusive, worldwide rights to develop and commercialize CX1632 . Cortex will receive $2 million up front, and is eligible for milestones and...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Company News

Cortex Pharmaceuticals, Servier deal

Servier paid Cortex $1 million for an option to purchase worldwide rights to jointly discovered CX1632 ( S47445 ) as well as a sub-license of Cortex's rights to all indications licensed from the University of...
07:00 , Mar 21, 2011 |  BC Week In Review  |  Company News

Cortex Pharmaceuticals, Valeant Pharmaceutical International Inc. deal

Cortex reacquired a portfolio of Ampakines for respiratory depression and related IP from Valeant. Valeant, which gained the assets through last year's merger with Biovail Corp. , discontinued the Ampakine program last November after it...
00:45 , Mar 17, 2011 |  BC Extra  |  Company News

Cortex reacquires Ampakines from Valeant

Cortex Pharmaceuticals Inc. (OTCBB:CORX) reacquired a portfolio of Ampakines for respiratory depression and related IP from Valeant Pharmaceuticals International Inc. (NYSE:VRX; TSX:VRX). Valeant, which gained the assets through last year's merger with Biovail Corp. ,...
08:00 , Dec 13, 2010 |  BioCentury  |  Strategy

Unwinding Biovail's Deals

Unwinding Biovail's Deals...
08:00 , Nov 8, 2010 |  BioCentury  |  Finance

Regulatory milestones

Regulatory milestones Adventrx Pharmaceuticals Inc. (NYSE-A:ANX) lost $0.03 to $2.07 last week after resubmitting an NDA to FDA for Exelbine vinorelbine injectable emulsion to treat non-small cell lung cancer (NSCLC). The company said the submission...
08:00 , Nov 8, 2010 |  BC Week In Review  |  Clinical News

CX717: Development discontinued

Valeant said it will not pursue further development of BVF-007 to treat respiratory depression. Valeant, which gained the Ampakine through its merger with Biovail Corp. this year, said the program did not fit with the...
00:26 , Nov 5, 2010 |  BC Extra  |  Top Story

Valeant continues to carve up Biovail

Valeant Pharmaceuticals International Inc. (NYSE:VRX; TSX:VRX) will reduce headcount by 29% and discontinue two additional development programs as part of its ongoing restructuring following its merger with Biovail Corp. in September. Valeant, which has already...